Haemonetics (NYSE:HAE – Get Free Report) and RxSight (NASDAQ:RXST – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.
Valuation & Earnings
This table compares Haemonetics and RxSight”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Haemonetics | $1.38 billion | 4.01 | $97.31 million | $2.23 | 54.63 |
| RxSight | $121.83 million | 1.74 | -$38.94 million | ($1.28) | -3.94 |
Volatility and Risk
Haemonetics has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, RxSight has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500.
Profitability
This table compares Haemonetics and RxSight’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Haemonetics | 7.52% | 27.42% | 9.77% |
| RxSight | -43.80% | -20.11% | -16.31% |
Insider & Institutional Ownership
99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 2.1% of Haemonetics shares are owned by insiders. Comparatively, 10.1% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and price targets for Haemonetics and RxSight, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Haemonetics | 0 | 3 | 9 | 1 | 2.85 |
| RxSight | 2 | 7 | 2 | 0 | 2.00 |
Haemonetics currently has a consensus target price of $130.50, indicating a potential upside of 7.12%. RxSight has a consensus target price of $6.94, indicating a potential upside of 37.66%. Given RxSight’s higher possible upside, analysts plainly believe RxSight is more favorable than Haemonetics.
Summary
Haemonetics beats RxSight on 12 of the 15 factors compared between the two stocks.
About Haemonetics
Haemonetics Corporation is a global medical technology company focused on blood and plasma collection, processing and management. Its products and services are used by plasma collection organizations, blood centers and hospitals. The company provides automated plasma collection systems and related software and supplies, as well as technologies for collecting and processing blood components. Its hospital offerings include devices for surgical blood salvage and tools that help clinicians assess blood clotting and guide transfusion decisions.
About RxSight
RxSight, Inc. is a medical technology company focused on products for cataract surgery and vision correction. Its main offering is the Light Adjustable Lens (LAL), an intraocular lens implanted during cataract surgery that can be adjusted after the procedure to refine a patient’s vision. Adjustments are made with RxSight’s Light Delivery Device, which uses ultraviolet light to change the lens’s optical power. The company also provides related treatment-planning and patient-care products and services for clinicians using the LAL system.
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.
